Therapeutic combination of a pneumocandin derivative and an antifungal agent
US7375081B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 21, 2005 |
| Grant date | May 20, 2008 |
| Priority date | — |
| Expiry date | Sep 5, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is described antifungal combination use of known antifungal agents such as the azoles or polyenes in combination with a lipopeptide compound antifungal agent. More particularly, the invention relates to antifungal combination use of azoles such as fluconazole, voriconazole, itraconazole, ketoconazole, miconazole, ER 30346 and SCH 56592; polyenes such as amphotericin B, nystatin, liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or nikkomycin X; other chitin inhibitors; elongation factor inhibitors such as sordarin and analogs thereof; mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127; or complex carbohydrate antifungal agents such as CAN-296; with a lipopeptide compound [I] as described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.